Campbell & Co Investment Adviser’s TG Therapeutics TGTX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-30,210	Closed	-$1.09M	–	1401
2025 Q3	$1.09M	Buy	+30,210	New	+$995K	0.08%	393
2024 Q2	–	Sell	-39,627	Closed	-$603K	–	1348
2024 Q1	$603K	Buy	+39,627	New	+$631K	0.05%	619
2023 Q4	–	Sell	-43,147	Closed	-$361K	–	1339
2023 Q3	$361K	Buy	+43,147	New	+$602K	0.04%	651

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Campbell & Co Investment Adviser's TGTX Position: Q4 2025 in Review

Campbell & Co Investment Adviser sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 30,210 shares — an estimated $1.09M sold.

Campbell & Co Investment Adviser first reported a position in TGTX in Q3 2023 and held it in 3 quarters. The position peaked at $1.09M in Q3 2025. 351 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

Campbell & Co Investment Adviser reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 30,210 TG Therapeutics shares in Q4 2025, an estimated $1.09M.
Campbell & Co Investment Adviser first reported a position in TG Therapeutics in Q3 2023 and held it in 3 quarters.
Campbell & Co Investment Adviser's TG Therapeutics position peaked at $1.09M in Q3 2025.
351 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q4 2025, filed 12 Feb 2026.